EPZ-5676 is an investigational drug that blocks a protein involved in leukemia growth called DOT1L. This protein is required for the growth of leukemias that contain an abnormal form of a gene called MLL. EPZ-5676 has shown promise against leukemia in laboratory studies and has also been evaluated in adult patients.
In this study, researchers want to find the highest dose of EPZ-5676 that can be given safely in children with acute leukemia that has come back or continued to grow despite prior treatment. EPZ-5676 is given via a continuous intravenous infusion over 28 days.